- Global Pharma News & Resources

Starch Medical Inc. European Patent Issued

Starch Medical Inc. a privately held manufacturer and marketer of polysaccharide based hemostatic products for use in controlling bleeding in surgery and trauma applications has announced the issuance of European Patent Number 2203053 for MODIFIED STARCH MATERIAL OF BIOCOMPATIBLE HEMOSTASIS. The patent is inclusive of Germany, France, Ireland and the United Kingdom and relates to the technology associated with the proprietary Absorbable Modified Polymers (AMP®) technology platform which consists of biocompatible, ultra-hydrophilic and adhesive hemostatic particles derived from purified plant starch. These devices include SealFoam® Absorbable Polysaccharide Hemostat, SealFoam® Sternal Absorbable Polysaccharide Hemostat, RESPONDER® Polysaccharide Hemostat, SuperClot® Absorbable Polysaccharide Hemostat and PerClot® Absorbable Polysaccharide Hemostatic System.

The ‘053 patent raises Starch Medical’s issued worldwide patents portfolio associated with the AMP® technology to 11.

The European patent for the starch based hemostatic technology accompanies previously issued patents in Japan, India, China and the United States.

“The market for polysaccharide hemostats is growing rapidly worldwide and especially in Europe where several competitive products have entered the market in the last few years,” stated Stephen Heniges, President at Starch Medical. “By adding to our IP portfolio this patent and its corresponding geographic coverage will assist our customers and partners to continue enjoying these technology benefits for many years to come.”

Starch Medical plans to enhance and expand its patent and product portfolio with innovative polymer based hemostatic technologies in the near future.

Additionally, next week Starch Medical will exhibit and hold distributor meetings at MEDICA, the world's leading trade fair for the medical industry held in Düsseldorf, Germany from November 12-15, 2018.

About Starch Medical Inc.

Starch Medical Inc. (SMI) was founded in 2007 and is a privately held San Jose, California based medical device company engaged in the design, manufacture and sale of absorbable hemostatic products. SMI has an independent distribution network for the sale of SealFoam® Absorbable Polysaccharide Hemostat, RESPONDER® Polysaccharide Hemostat and SuperClot® Absorbable Polysaccharide Hemostat.

View source version on

Editor Details

Last Updated: 07-Nov-2018